Across TCGA pan-cancer cohorts, IER5L Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IER5L data layer compared with 26 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher IER5L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IER5L expression acts as an unfavorable survival marker.
SKCM are the cancer types where IER5L Mutation most reproducibly stratifies survival.